文献速递淋巴瘤

Loncastuximab tesirine治疗经多线治疗的大B细胞淋巴瘤:德国淋巴瘤联盟真实世界分析

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.
PubMed 文献 · Blood Adv · 2026-09-18

总缓解率27%,完全缓解率10%,中位无进展生存2.2个月,中位总生存4.4个月。≥3级感染最常见(13%),后续接受异基因移植者生存更优。

要点

  • 经多线治疗的大B细胞淋巴瘤患者中,lonca总缓解率27%,完全缓解率10%。
  • 中位无进展生存2.2个月,中位总生存4.4个月,缓解者中位无进展生存11.4个月。
  • 后续接受异基因移植者中位总生存15.2个月,优于未巩固者的3.8个月(p=0.048)。

核心结论

  • Lonca在经多线治疗的大B细胞淋巴瘤患者中安全性良好,疗效中等。
  • Lonca可为患者争取后续治疗时机,与联合方案在更早线应用可能提高缓解率与缓解持续时间。

研究设计与样本

  • 德国淋巴瘤联盟真实世界分析,纳入31个德国中心的数据。
  • 76%的患者曾接受CAR-T(n=55)、双特异性抗体(n=56)或两者(n=40)。

主要发现

  • 总缓解率为27%,完全缓解率为10%。
  • 中位无进展生存期2.2个月,中位总生存期4.4个月。
  • 缓解者的中位无进展生存期为11.4个月。
  • ≥3级感染发生率为13%,为最常见不良事件。
  • 后续接受异基因干细胞移植者中位总生存期15.2个月,未巩固者3.8个月(p=0.048)。

关键数值与推荐

  • 多因素分析中,对lonca前末线治疗无缓解与总生存差显著相关(HR=2.5,p=0.014)。
  • 继发性IPI与无进展生存和总生存差显著相关(HR≥2.0,p≤0.024)。

临床怎么用

  • Lonca可作为经多线治疗的大B细胞淋巴瘤患者的桥接治疗,以争取后续异基因移植等治疗机会。
  • 对lonca前末线治疗无缓解及继发性IPI较高的患者,需警惕预后不佳。

局限性

  • 未报告对照组的比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with large B-cell lymphoma progressing after multiple lines of therapy few treatment options remain, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pre-treated patients received lonca in third and later line of therapy. 76% had received treatment with chimeric antigen receptor T-cells (n=55), bispecific antibodies (BsAbs) (n=56) or both (n=40). The overall response rate was 27% and complete response rate was 10%. Median progression-free (mPFS) and overall survival (mOS) were 2.2 and 4.4 months, respectively. Median PFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥ 3 infections (13%) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly better than the remaining non-consolidated patients (mOS: 15.2 vs. 3.8 months, p=0.048). In multivariable analysis, no response to the last therapy prior to lonca (OS - HR: 2.5, p=0.014) and secondary IPI (PFS/OS - HR: ≥2.0, p≤0.024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. While enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shumilov E, Kolloch L, Faustmann P, et al. Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis. Blood Adv. 2026. PMID: 42759142. doi:10.1182/bloodadvances.2026020742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。